EXPLORE!

ADA-EASD 2018 Consensus - In Indian Context

  1469 Views

Dr Awadhesh K Singh, Kolkata    21 November 2018

  1. Sulfonylureas (SUs) and thiazolidinediones (TZDs) remain the cornerstone of therapy in a developing country where the patient has to pay from his pocket.
  2. Alpha-glucosidase inhibitors (AGIs) are not included in ADA-EASD consensus as they are not used in the USA, but are still useful in Indians.
  3. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and SGLT-2i should be used in established CVD, given the data we have.
  4. SGLT-2i have data suggestive of prevention of hospitalization for HF in T2DM and thus should be used if patients can afford.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.